T-cell engagers (TCEs) are rapidly becoming a powerful immunotherapy platform, showing meaningful clinical responses across multiple tumor types. Yet their...

A new photodynamic therapy strategy could make cancer treatment less vulnerable to one of the tumor’s most reliable defenses: low...

A new study suggests that the way cancer cells run their mitochondria—tiny energy factories inside the cell—can predict how well...

Tumour biopsy remains the clinical gold standard for diagnosing cancer and guiding biomarker-based treatment choices. By interrogating the tumour itself,...

Pancreatic cancer is notoriously resistant to immunotherapy because many tumors develop an immune-suppressive, oxygen-poor “cold” microenvironment that blocks effective T...

A new spatial genomics platform is aiming to make cancer immunotherapy more precise by revealing where, in a patient’s tumor,...

A new analysis from a large, single-centre cohort suggests that when immune checkpoint inhibitors are given can meaningfully shape outcomes...

A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with...

Reston, VA (July 17, 2026)—A set of studies released ahead of print in The Journal of Nuclear Medicine (JNM) highlights...

Advanced colorectal cancer remains one of oncology’s toughest challenges, especially in pathological T4 (pT4) disease where outcomes are often grim....